Jacoline B.
- Country
- The Netherlands
- Department
- Neurology
Research Overview
- ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (The ACTION Study)
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Vorasidenib in Residual or Recurrent Grade 2 Glioma with IDH1/IDH2 Mutation
Data & Insights
Has run more than one trial at 10 of 34 partner sites.
Specializations
Neuro-Oncology Focus
The investigator specializes in the treatment of diffuse gliomas, with particular emphasis on H3 K27M-mutant variants of these brain tumors.
- Brain Tumor Treatment
- Molecular Targeted Therapy
- Post-Radiation Treatment Strategies
Their research encompasses innovative therapeutic approaches for patients with specific genetic mutations in brain tumors.
Precision Medicine
The investigator focuses on developing targeted treatments for mutation-specific brain cancers, particularly exploring novel therapeutic agents in glioma treatment.
- Genetic Mutation Analysis
- Personalized Treatment Approaches
- Advanced Therapeutic Strategies
Their work integrates molecular diagnostics with therapeutic interventions in neuro-oncology.
Treatment Integration
The investigator explores the integration of radiotherapy with targeted treatments in brain cancer therapy, focusing on optimizing treatment sequences.
- Combined Therapy Approaches
- Post-Radiation Interventions
- Treatment Timing Optimization
Their expertise includes coordinating multiple treatment modalities for enhanced therapeutic outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.